I think your speaking of another company. Below is who we are merging with.
On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp
(“ANEW”), including the wholly own subsidiaries ANEW Oncology, Inc. and Anew Gene Therapy Inc., whereby
each issued and outstanding share of ANEW common stock was converted into the right to receive one-one
hundredth (1/100) of a share of the Company’s Series B preferred stock, par value $.001 per share. On November
1, 2021, the total ANEW stock issued and outstanding was 40,525,000 shares which was converted into 405,250
shares of the Company’s Series B preferred stock.
The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for
financial statement reporting purposes. Accordingly, the ANEW’s assets, liabilities and results of operations
became the historical financial statements of the Company. The Company’s name will be changed to ANEW
Medical, Inc. The 1,044,861,360 outstanding shares of Company’s common stock prior to the Agreement and
Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.
